Bank of New York Mellon Corp - NOVOCURE LTD ownership

NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 316 filers reported holding NOVOCURE LTD in Q4 2022. The put-call ratio across all filers is 1.54 and the average weighting 0.2%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of NOVOCURE LTD
ValueSharesWeighting
Q2 2024$7,193,923
+71.9%
419,960
+56.8%
0.00%0.0%
Q1 2024$4,185,324
-10.7%
267,775
-14.7%
0.00%0.0%
Q4 2023$4,686,721
-19.9%
313,913
-13.4%
0.00%0.0%
Q3 2023$5,854,068
-68.0%
362,481
-17.7%
0.00%
-75.0%
Q2 2023$18,279,175
-31.9%
440,462
-1.3%
0.00%
-33.3%
Q1 2023$26,839,941
-19.6%
446,291
-1.9%
0.01%
-25.0%
Q4 2022$33,367,840
-6.5%
454,913
-3.2%
0.01%
-11.1%
Q3 2022$35,690,000
+31.1%
469,746
+19.9%
0.01%
+50.0%
Q2 2022$27,233,000
+0.1%
391,847
+19.4%
0.01%
+20.0%
Q1 2022$27,195,000
+9.1%
328,244
-1.2%
0.01%
+25.0%
Q4 2021$24,935,000
-34.4%
332,104
+1.4%
0.00%
-42.9%
Q3 2021$38,030,000
-47.8%
327,363
-0.3%
0.01%
-50.0%
Q2 2021$72,797,000
+52.0%
328,185
-9.4%
0.01%
+40.0%
Q1 2021$47,883,000
-30.2%
362,253
-8.7%
0.01%
-33.3%
Q4 2020$68,624,000
+85.3%
396,579
+19.2%
0.02%
+66.7%
Q3 2020$37,040,000
+109.7%
332,768
+11.7%
0.01%
+80.0%
Q2 2020$17,665,000
-23.0%
297,893
-12.5%
0.01%
-37.5%
Q1 2020$22,936,000
-23.4%
340,600
-4.1%
0.01%0.0%
Q4 2019$29,945,000
+13.2%
355,340
+0.5%
0.01%
+14.3%
Q3 2019$26,452,000
+10.6%
353,731
-6.5%
0.01%0.0%
Q2 2019$23,923,000
+43.8%
378,356
+9.6%
0.01%
+40.0%
Q1 2019$16,635,000
+50.0%
345,338
+4.2%
0.01%
+66.7%
Q4 2018$11,093,000
-45.3%
331,349
-14.4%
0.00%
-40.0%
Q3 2018$20,292,000
+77.2%
387,258
+5.8%
0.01%
+66.7%
Q2 2018$11,453,000
+163.9%
365,923
+83.8%
0.00%
+200.0%
Q1 2018$4,340,000
-14.3%
199,089
-20.6%
0.00%0.0%
Q4 2017$5,065,000
+25.7%
250,707
+23.5%
0.00%0.0%
Q3 2017$4,030,000
+16.3%
203,031
+1.4%
0.00%0.0%
Q2 2017$3,465,000
+146.4%
200,307
+15.4%
0.00%
Q1 2017$1,406,000
+4.7%
173,523
+1.4%
0.00%
Q4 2016$1,343,000
+2.6%
171,043
+11.6%
0.00%
Q3 2016$1,309,000
-18.2%
153,307
+11.8%
0.00%
Q2 2016$1,600,000
+381.9%
137,091
+498.6%
0.00%
Q1 2016$332,000
-5.4%
22,901
+45.8%
0.00%
Q4 2015$351,00015,7050.00%
Other shareholders
NOVOCURE LTD shareholders Q4 2022
NameSharesValueWeighting ↓
StepStone Group LP 1,365,479$29,767,00021.90%
Tamarack Advisers, LP 1,115,000$24,307,00011.56%
COURAGE CAPITAL MANAGEMENT LLC 275,000$5,995,0004.57%
GREAT POINT PARTNERS LLC 753,481$16,426,000,0002.44%
HARTLINE INVESTMENT CORP/ 404,052$8,808,0002.42%
Pier Capital, LLC 346,350$7,550,0001.29%
Rhenman & Partners Asset Management AB 435,000$9,483,0001.17%
HIGHLINE CAPITAL MANAGEMENT, L.P. 1,029,910$22,452,0000.77%
PEREGRINE CAPITAL MANAGEMENT LLC 922,468$20,110,0000.49%
Hodges Capital Management Inc. 285,500$6,224,0000.49%
View complete list of NOVOCURE LTD shareholders